Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Purpose: Registered trials and real-world evidence (RWE) studies provided evidence on the efficacy of once-weekly (OW) semaglutide on hyperglycaemia and cardiovascular risk factors as add-on or de-novo treatment in type 2 diabetes (T2D). Methods: In a retrospective analysis of electronic data files from 258 T2D patients, this RWE study aimed to explore the impact of OW semaglutide on biochemical and anthropometric outcomes after 6 and 12 months in patients receiving at least one prescription of OW semaglutide between September 2019 and May 2021. Results: During the study period, 154 and 56 consecutive patients completed the 6 and 12 months of OW semaglutide treatment. HbA1c levels decreased by -1.02±0.1% after 6 months and -1.1±0.1% after 12 months of OW semaglutide ( p <0.0001 for both). At these time-points, HbA1c values were <7% in 61% and 57% of cases. HbA1c reduction was greater in patients with higher baseline HbA1c levels and it occurred irrespective of gender, age, insulin therapy and complications. The residual number of cases with HbA1c ≥9% by the study end was low (5.3% vs 18.9% at baseline). Weight loss occurred in 73.5% and 78.1% of cases and, compared to baseline, it was ≥5% in 21.2- 25.4% and ≥10% in 6.8-18.2% after 6 and 12 months, respectively. Significant predictors of HbA1c reduction after 6 months of OW semaglutide treatment were baseline HbA1c ( p <0.0001), bodyweight reduction ( p <0.0001) and disease duration ( p <0.001), while baseline HbA1c was the only predictor of HbA1c response after 12 months ( p <0.0001). Reported adverse events were consistent with the known safety profile of semaglutide. Conclusions: Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997
Kristensen, S. L., Rørth, R., Jhund, P. S., Docherty, K. F., Sattar, N., Preiss, D., Køber, L., Petrie, M. C., & McMurray, J. J. V. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30249-9 · Cited by 1,663
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“Marketing of OW semaglutide has been granted in Europe since February 2018 and has been available for therapeutic use in Italy since September 2019 [15, 16].”
BackgroundPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30085-2 · Cited by 464
Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial.
Rodbard, H. W., Lingvay, I., Reed, J., de la Rosa, R., Rose, L., Sugimoto, D., Araki, E., Chu, P.-L., Wijayasinghe, N., & Norwood, P. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00070 · Cited by 412
Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., Lingvay, I., Thomsen, M., Wadden, T. A., Wharton, S., et al. (2020) · Obesity · doi:10.1002/oby.22794 · Cited by 288
Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000920 · Cited by 192
Cook, M. N., Girman, C. J., Stein, P. P., Alexander, C. M., & Holman, R. R. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.995 · Cited by 187 · cited 1×
“As such, older patients with a long history of disease and previously exposed to insulin-secretagogues may show lower response to drugs other than insulin [56].”
BackgroundMann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S., & Vilsbøll, T. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30313-2 · Cited by 157 · cited 1×
“Others reported similar results [25, 32] and post-hoc analyses suggested that OW semaglutide can initially decrease eGFR while promoting reductions in UACR [55].”
ResultMethods of Estimating GFR - Different Equations Including CKD-EPI.
Florkowski, C. M., & Chew‐Harris, J. (2011) · Europe PMC (PubMed Central) · Cited by 150
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
(2017) · New England Journal of Medicine · doi:10.1056/nejmc1615712 · Cited by 144
Honigberg, M. C., Chang, L.-S., McGuire, D. K., Plutzky, J., Aroda, V. R., & Vaduganathan, M. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.1966 · Cited by 127
Gut hormone polyagonists for the treatment of type 2 diabetes
Brandt, S. J., Götz, A., Tschöp, M. H., & Müller, T. D. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.021 · Cited by 111
Creating and using real-world evidence to answer questions about clinical effectiveness
De Lusignan, S., Crawford, L., & Munro, N. (2015) · Journal of Innovation in Health Informatics · doi:10.14236/jhi.v22i3.177 · Cited by 82
Oral semaglutide in type 2 diabetes
Anderson, S. L., Beutel, T. R., & Trujillo, J. M. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107520 · Cited by 79 · cited 1×
“Confirming the vast interest aroused by semaglutide in the treatment of diabetes and obesity, an oral formulation semaglutide has been recently introduced [51], which is particularly useful for patients who dislike injections, and major medicines regulatory agencies have recently granted approval for the use of OW sem…”
BackgroundAlbuminuria and Carotid Atherosclerosis as Predictors of Cognitive Function in a General Population
Rogne, S. O., Solbu, M. D., Arntzen, K. A., Herder, M., Mathiesen, E. B., & Schirmer, H. (2013) · European Neurology · doi:10.1159/000353701 · Cited by 66
Zavattaro, M., Caputo, M., Samà, M. T., Mele, C., Chasseur, L., Marzullo, P., Pagano, L., Mauri, M. G., Ponziani, M. C., Aimaretti, G., et al. (2015) · Endocrine · doi:10.1007/s12020-014-0519-0 · Cited by 63
Self-citationRajamand Ekberg, N., Bodholdt, U., Catarig, A.-M., Catrina, S.-B., Grau, K., Holmberg, C. N., Klanger, B., & Knudsen, S. T. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2021.06.008 · Cited by 63
Uzoigwe, C., Liang, Y., Whitmire, S., & Paprocki, Y. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01053-7 · Cited by 62
DeSouza, C., Cariou, B., Garg, S., Lausvig, N., Navarria, A., & Fonseca, V. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz072 · Cited by 57 · cited 1×
“8% of cases after 6–12 months of treatment [53], recent retrospective observational studies documented a mean HbA1c reduction of 0.”
BackgroundIacobellis, G., & Baroni, M. G. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01687-1 · Cited by 56
Jain, A. B., Kanters, S., Khurana, R., Kissock, J., Severin, N., & Stafford, S. G. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00984-x · Cited by 47
Rudofsky, G., Catarig, A.-M., Favre, L., Grau, K., Häfliger, S., Thomann, R., & Schultes, B. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108931 · Cited by 46
Hunt, B., Malkin, S. J. P., Moes, R. G. J., Huisman, E. L., Vandebrouck, T., & Wolffenbuttel, B. H. R. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000705 · Cited by 42
Brown, R. E., Bech, P. G., & Aronson, R. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14117 · Cited by 42
Holmes, P., Bell, H. E., Bozkurt, K., Catarig, A.-M., Clark, A., Machell, A., & Sathyapalan, T. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01141-8 · Cited by 42
Lingvay, I., Kirk, A. R., Lophaven, S., Wolden, M. L., & Shubrook, J. H. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01010-4 · Cited by 41
Yale, J., Catarig, A., Grau, K., Harris, S., Klimek‐Abercrombie, A., Rabasa‐Lhoret, R., Reardon, L., Woo, V., & Liutkus, J. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14468 · Cited by 37
Pineda, E. D., Liao, I., Godley, P. J., Michel, J. B., & Rascati, K. L. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.5.610 · Cited by 35
Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity.
Nolen-Doerr, E., Stockman, M.-C., & Rizo, I. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00350-4 · Cited by 32 · cited 1×
“Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are recognized glucose-lowering agents that act through pancreatic and extra-pancreatic mechanisms, these latter including decrease of gastric motility and central control of food intake [3].”
BackgroundTilinca, M. C., Tiucă, R. A., Niculas, C., Varga, A., & Ţilea, I. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10601 · Cited by 32
Aroda, V. R., Capehorn, M. S., Chaykin, L., Frias, J. P., Lausvig, N. L., Macura, S., Lüdemann, J., Madsbad, S., Rosenstock, J., Tabak, O., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13896 · Cited by 31
Renal protection with glucagon-like peptide-1 receptor agonists
Vitale, M., Haxhi, J., Cirrito, T., & Pugliese, G. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.018 · Cited by 31 · cited 1×
“Further, treatment with GLP-1RAs benefits kidney protection through reduction of albuminuria, as well as by controlling progression of diabetic kidney disease (DKD) to end-stage renal disease (ESRD) independent of albuminuria [9].”
BackgroundWilliams, D. M., Ruslan, A. M., Khan, R., Vijayasingam, D., Iqbal, F., Shaikh, A., Lim, J., Chudleigh, R., Peter, R., Udiawar, M., et al. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01015-z · Cited by 31 · cited 3×
“Recent RWE have shown similar effects on weight [25, 32].”
BackgroundResultHansen, K. B., Svendstrup, M., Lund, A., Knop, F. K., Vilsbøll, T., & Vestergaard, H. (2021) · Diabetic Medicine · doi:10.1111/dme.14655 · Cited by 23 · cited 2×
“3%, a marginal figure that is comparable to rates recorded in registry-based studies [24, 26].”
ResultEfficacy of semaglutide versus liraglutide in clinical practice
Gonçalves, E., & Bell, D. S. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.10.001 · Cited by 20
Visaria, J., Uzoigwe, C., Swift, C., Dang-Tan, T., Paprocki, Y., & Willey, V. J. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.03.003 · Cited by 20 · cited 1×
“3%, a marginal figure that is comparable to rates recorded in registry-based studies [24, 26].”
ResultEfficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes
Tan, X., Cao, X., Zhou, M., Zou, P., & Hu, J. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1360274 · Cited by 18
Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study
Hepprich, M., Zillig, D., Florian-Reynoso, M. A., Donath, M. Y., & Rudofsky, G. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01016-y · Cited by 18
Hayek, A. A., & Dawish, M. A. A. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02053-0 · Cited by 15
Oral GLP1 Analog: Where Does the Tide Go?
Gardner, H. M., & Hamdy, O. (2020) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/1179551420984130 · Cited by 15
Tofé, S., Argüelles, I., Mena, E., Serra, G., Codina, M., Urgelés, J. R., García, H., & Pereg, V. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100082 · Cited by 9
Wang, W., Wen, X., Duan, W., Wang, X., Chen, Y., Dong, J., Yang, Z., Fang, J., Zhou, Z., Yao, G., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01153-z · Cited by 5
Ferrer-García, J. C., Albalat-Galera, R., Arribas, L., Tolosa-Torréns, M., LORENTE, A. S., Portilla, A. J., Artero, A., & Sánchez-Juan, C. (2020) · Diabetes · doi:10.2337/db20-947-p · Cited by 3
de Lucas, M. D. G., Perez-Belmonte, L. M., Avilés, B., Jímenez, A. I., Fernández, J. M. R., & Rivas‐Ruiz, F. (2021) · Diabetes · doi:10.2337/db21-676-p · Cited by 3
690-P: Semaglutide in Patients with Type 2 Diabetes: Real-World Data from Spain
Cárdenas‐Salas, J., SIERRA, R., Luca, B. L., SANCHEZ, B., Móstoles, N. M., Casado, C., SANCHEZ, N. M., Cruces, V. E., & Vázquez, C. (2021) · Diabetes · doi:10.2337/db21-690-p · Cited by 2
Tong, J., Jain, A., & Stafford, S. G. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.08.061 · Cited by 1
Valencia, C. M. B., Zambrano, J., García, A. F. S., & Casanova, M. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154640 · Cited by 1
Crabtree, T. S. J., Bickerton, A. S. T., SENNIK, D. K., Rohilla, A., Sivappriyan, S., Barnes, D., CULL, M. L., GALLEN, I. W., Adamson, K., & Ryder, R. E. J. (2021) · Diabetes · doi:10.2337/db21-686-p · Cited by 1
Cited by
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Effectiveness and safety of drugs for obesity
Henderson Lewis, K., Sloan, C. E., Bessesen, D. H., & Arterburn, D. (2024) · BMJ · doi:10.1136/bmj-2022-072686 · Cited by 66
Napoli, R., Berra, C., Catarig, A., Di Loreto, C., Donatiello, E., Berentzen, T. L., Pitocco, D., & Giorgino, F. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15020 · Cited by 32
Alexander, G. C., Xiao, X., Dilek, S., Lewis, S. V., Deng, Q., Kim, M., Bolanle, D., Saldanha, I. J., & Mehta, H. B. (2026) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.8222 · Cited by 30
Berra, C. C., Rossi, M. C., Mirani, M., Ceccarelli Ceccarelli, D., Romano, C., Sassi, L., Peretti, E., Favacchio, G., Pastore, I., Folini, L., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1099451 · Cited by 28
Metadata
- Authors
- Marzullo, P., Daffara, T., Mele, C., Zavattaro, M., Ferrero, A., Caputo, M., Prodam, F., & Aimaretti, G.
- Affiliations
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Azienda Ospedaliero Universitaria Maggiore della Carita (IT)
- Corresponding author
- Marzullo, P.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2022-04-16
- Volume
- 45
- Issue
- 8
- Pages
- 1587-1598
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- PMC
- PMC9270295
- OpenAlex
- W4224120703
- Semantic Scholar
- 2cbcda3fbbbe7a50a204bd17375bafbd1ce0b335
- Cited by
- 34
- References
- 62
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 6 · 2023: 10 · 2022: 3
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Endocrinological Investigation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Open access funding provided by Università degli Studi del Piemonte Orientale Amedeo Avogrado within the CRUI-CARE Agreement.
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, type 2 diabetes, HbA1c reduction, glycemic control, weight loss, GLP-1 receptor agonists, real-world evidence, predictors of treatment response, adverse events, Italian patients, insulin therapy, disease duration, cardiovascular risk factors, hyperglycemia, predictors of weight loss
- MeSH terms
- Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Retrospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.